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ABSTRACT    
Myxoid changes have been rarely reported both in adrenocortical adenomas and carcinomas. The 
recent observation by our group of an adrenal myxoid tumor with morphologically borderline 
features but aggressive clinical behavior prompted us to review a series of 196 adrenocortical 
lesions, comprising 122 carcinomas and 74 adenomas, to define the morphological, phenotypical 
and clinical characteristics of adrenocortical tumors with myxoid features. Fourteen cases, including 
12 carcinomas and 2 borderline tumors, formed the basis of this report, and were characterized by a 
variably abundant myxoid component (from 5% to 90% of tumor) and two distinct cellular growth 
patterns: the first (10 cases), mostly associated with a predominant myxoid stromal component, was 
made of small cells with mild atypia arranged in cords and microcysts; the second (4 cases) was 
characterized by focal myxoid changes in tumors otherwise similar to conventional adrenocortical 
carcinoma, with large atypical cells having an eosinophilic cytoplasm and a diffuse or nodular 
architecture. The above mentioned patters were absent in all adenomas reviewed. A peculiar 
reactivity to neurofilaments was seen, mostly associated to the presence of predominant rather that 
focal myxoid stromal changes, as well as in 40% of conventional adrenocortical carcinomas, thus 
representing an undescribed potential pitfall in the differential diagnosis of adrenal lesions. Myxoid 
adrenocortical tumors probably represent a rare but histologically and phenotipically distinct entity 
and, although rare cases of benign lesions are on record, they seem to be generally associated to 
morphological and clinical features of malignancy. 
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INTRODUCTION 
Varying degrees of myxoid change have been reported in adrenocortical tumors (ACT), either 
as focal cell aggregates in an alcianophilic material of an otherwise conventional adrenocortical 
adenoma (ACA) or carcinoma (ACC), or - much more rarely - as pure myxoid tumors made of 
small-sized cell cords or pseudoglands embedded in an abundant extracellular myxoid matrix. 
Following the original report by Tang and coworkers (26), 32 functioning or non-functioning 
myxoid ACT have been described, including 18 adenomas, 13 carcinomas and one borderline case 
(3,4,6,7,9,10,13-17,19,23,25,30). Myxoid changes may also be present in pediatric ACT, judging 
from the images (Fig. 1D) shown in a recent review article (5). 
While the overall immunoprofile of these tumors does not differ from that of conventional 
ACT (melan A, α-inhibin, synaptophysin and vimentin being generally expressed), the morphology 
of myxoid ACT is challenging, since several other tumor entities may enter in the differential 
diagnosis, and the application of the so-called Weiss criteria (28,29) may not be easy to apply to 
pure myxoid tumors due to the limited degree of atypia, lack of diffuse growth, and hard-to-assess 
sinusoidal invasion. To date, the treatment of these neoplasms is not different from that of 
conventional ACA and ACC, but the real nature of these myxoid variants is far from being 
understood. Indeed, it is not well established whether the myxoid changes represent a variant of 
either  ACA or ACC, or if the myxoid changes by themselves point to a specific tumor type with a 
distinct biological behavior within the group of primary ACT. 
A few years ago, some of us (MP, MT) reported a myxoid ACT lacking morphological signs 
of malignancy (Weiss score 1) that was interpreted as a myxoid ACA (3). Four years later, the 
patient developed a diffuse abdominal neoplastic spread which could not be resected. A fine needle 
aspiration biopsy of the mass showed a diffuse growth of small-medium size cells with 
hyperchromatic nuclei and no myxoid background. Originally this tumor was tentatively interpreted 
as a primary abdominal small round cell tumor (11), based on the focal expression of CD99 and 
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neurofilaments. However, the finding of adrenocortical marker expression (including melan A and 
α-inhibin) led to a revised diagnosis of metastatic ACT. 
This prompted a review of all ACT filed at the San Luigi Hospital and University of Turin 
Medical School, which serves as a national referral center for ACC, with the aims of: a) identifying 
other pure or combined myxoid ACT; b) evaluating the immunoprofile of these neoplasms, with 
special reference to the expression of neural markers, in comparison with the expression profiles of 
normal adult and fetal adrenal glands; c) analyzing the clinical and pathological features of myxoid 
ACT, as compared to conventional ACA and ACC. 
 
MATERIAL AND METHODS 
Sample case (case #1) – In 2002, a 58-year-old male patient underwent resection of a well 
circumscribed right adrenal mass (55 g; 5 cm). Microscopically, a myxoid tumor with trabecular, 
microcystic and pseudoglandular growth patterns was found having a low Ki-67 proliferation index  
and an immune profile consistent with an adrenocortical origin. Based on the tumor size and the 
final Weiss score (28,29) of 1 (clear cell cytoplasm in less than 25% of tumor), a diagnosis of ACT 
of uncertain malignant potential with myxoid changes was made, and no additional treatment was 
administered. Two years later, this case was reported as an example of myxoid ACA (3). The 
patient was temporarily lost to follow up, but on December 2007 he reappeared complaining of 
abdominal pain. Imaging procedures revealed a large abdominal tumor partially engulfing the small 
intestine, with diffuse peritoneal carcinomatosis. A fine needle aspiration biopsy revealed a small 
round cell tumor devoid of myxoid material. The limited immunocytochemical panel performed at 
the time on the cell block was as follows: pancytokeratin negative, CD99 and neurofilaments 
positive (initially thought to support a diagnosis of intra-abdominal small round cell tumor), melan 
A and α-inhibin positive. The clinical and pathological findings were thought to be consistent with 
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abdominal spread of the myxoid ACT and the patient was treated with mitotane, but eventually died 
of his tumor in 2008, 68 months after the original diagnosis.  
Myxoid ACT series (cases # 2 to 14) - From 1990 to 2009, 122 consecutive ACC were found in the 
pathology files of the University of Turin at San Luigi hospital, for which either glass slides or 
paraffin blocks were available for review. This series included 35 ACC resected at our hospital, 63 
cases received in consultation from different Italian hospitals, and 24 ACC originally collected by 
one of us (MP) at the St Giovanni Hospital of Turin in years 1993-2003. The majority of these cases 
were treated at our Institution, which serves as a referral center for adrenocortical carcinoma in 
Italy. The group of ACA included 74 consecutive tumors diagnosed at our Institution during the 
same time-period. Twenty of them were characterized by the presence of either large size (> 5 cm) 
or a Weiss score of 1 or 2 (i.e. still in the benign range). The histopathological features of 92 ACC 
and of 47 ACA belonging to this data set have recently been reported (27). 
Case review – All cases of ACC and ACA were reviewed by two of us (MP and MV) using a mean 
of 5.2 hematoxylin-eosin-stained slides per case (range 1-30) for the carcinomas and a mean of 3.2 
slides per case for the adenomas (range 1-8). Before review, all tissue blocks were de-identified and 
coded by a pathology staff member not involved in the study, so that all cases were made 
anonymous to the investigators. In the group of ACA, no myxoid changes were identified, except 
for one case (case #2) represented by a 4 cm non-functioning tumor with a Weiss score of 1, which 
was diagnosed as a borderline ACT. In the group of ACCs, myxoid changes, either focal or 
extensive, were found in 12 cases (10%), which - together with the above described case #1 and the 
borderline case (case #2) – form the basis for this study.  From all cases, clinico-pathological data 
(including information on treatment and outcome) were obtained and analysed. The study was 
approved by the local Review Board of our Institution. 
Normal adrenal glands –  In addition to the adrenal gland tissue present in the peritumoral 
peripheral areas of most cases, two apparently normal adrenal glands from adult patients operated 
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for renal cell carcinoma, one ectopic adrenal tissue incidentally found in the spermatic cord of a 
patient operated for testicular seminoma and 8 fetal adrenal glands (10-26 weeks of gestation from 
cases of spontaneous or therapeutic abortions) were also investigated, using the same markers 
applied to the tumors, as listed below. All tissue blocks were coded by a pathology staff member 
not involved in the study, so that all normal adrenal gland cases were made anonymous to the 
investigators. 
Immunohistochemistry – Sections serial to those used for conventional hematoxylin-eosin and 
histochemical stains (Alcian blue and reticulin stains) were obtained from one or two representative 
tissue blocks of most cases (only the immunoprofile of cases # 6 and 8 could not be completely 
investigated). The following antibodies were employed: pan-cytokeratin (DakoCytomation, 
Glostrup, Denmark, clone AE1/AE3, diluted 1/100), vimentin (Dako, clone V9, diluted 1/350), 
melan A (Dako, clone A103, diluted 1/350), α-inhibin (Diamedix, Miami, USA, clone R1, diluted 
1/75), synaptophysin (Dako, clone SY38, diluted 1/100), chromogranin A (Abcam, Cambridge, 
USA, clone LK2H10, diluted 1/500), Ki67 (Dako, clone MIB-1, diluted 1/150), neuron specific 
enolase (NSE; Neomarkers, Fremont, USA, clone E27, diluted 1/600), CD56 (Novocastra-Leica, 
Milan, Italy, clone 1B6, diluted 1/150), CD57 (Zymed, San Francisco, USA, clone NK-1, diluted 
1/50), CD99 (Dako, clone MIC-2, diluted 1/100), synapsin (Novocastra, clone A10C, diluted 
1/150), hASH1 (BD Pharmingen, San Diego, USA, clone 24BD72D11.1, diluted 1/150). Finally, 
total neurofilament proteins were tested either as a pool, including 68 kDa, 160 kDa, 200 kDa 
subunits, or as each single neurofilament subunit (subunit 68 kDa, Neomarkers, clone NR4, diluted 
1/500; subunit 160 kDa, Progen, Ancona, Italy, clone NN18, diluted 1/100; subunit 200 kDa, 
Progen, clone NE14, diluted 1/500). Antigen retrieval procedure using microwave heating (3 five 
min passages at 750 Watt) in citrate buffer solution (pH 6.0) was performed for all antibodies. A 
biotin-free, dextran chain detection system (EnVysion, Dako) was used according to a standard 
procedure, and diaminobenzidine was employed as a chromogen. In case #2 and in a fetal adrenal 
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sample, a double immunohistochemical stain was performed to reveal melan A and neurofilaments 
in the same section, using sequential immunoperoxidase and immunoalkaline phosphatase detection 
systems, and 3-amino,9-ethylcarbazole and nitroblue tetrazolium salts, as chromogens, respectively. 
The immunophenotype (namely neurofilaments) of myxoid tumors was compared to that of 
conventional ACC in a control group of 47 randomly selected ACC cases, using a tissue microarray 
(TMA). 
 
RESULTS 
Clinical data (Table 1) – The 14 tumors affected 5 males and 9 females, with a median age of 53 
years (range 43-72). The tumors were located in the right adrenal gland in five cases and in the left 
gland in nine. The hormonal status was known for all patients, and a functioning tumor was found 
in 10 cases (71%). Cortisol production was the most common event (nine patients), while androgen 
production was observed in three patients (two of them had concomitant hypercortisolism). The 
tumors were generally large, ranging from 4 to 30 cm in largest diameter (mean 12.5 cm). The mean 
weight of the 12 tumors in which this information was available was 848 g, ranging from 20 to 
3200 g.  
The clinical history of case #1 case was reported above. The other borderline case (case #2) was a 
52-year-old female patient who was recently found to be affected by a 4 cm non-functioning tumor 
of her left adrenal gland. The patient had no additional therapies after surgery and is under close 
follow up, being currently free of disease nine months after operation. 
At the time of diagnosis, five patients had an early stage tumor, while seven had locally advanced or 
metastatic disease. All but two patients had surgery as primary treatment, attaining a radical 
resection in nine cases, who became disease-free. Surgery was also performed after diagnosis in  
four patients with metastatic disease: one of these had a radical resection of either primary or 
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metastatic disease, while in the remaining patients surgery was performed for tumor debulking 
purposes, in order to control the endocrine syndrome and/or favor the subsequent systemic therapy. 
Except for the borderline tumors, a systemic antineoplastic treatment was administered to 11 of 12 
patients (excluding case #11). Single agent mitotane was administered orally to five patients (3 of 
them had metastatic disease), tailoring the dose in each patient to attain and maintain circulating 
drug levels within the therapeutic range (14-20 ng/ml). Patients with metastatic ACC had disease 
progression despite mitotane therapy and did not receive concomitant chemotherapy because of 
their poor clinical conditions. Six other patients with metastatic disease received mitotane in 
combination with an etoposide, adriamycin and cisplatin (EDP-M) chemotherapy regimen (1). After 
six chemotherapy cycles, three patients showed a partial response (i.e. tumor shrinkage greater than 
30%), one obtained a short lived (2 months) disease stabilization and one progressed. The 
remaining patient interrupted the treatment after 3 cycles due to disease progression. She was then 
addressed to a second line chemotherapy with gemcitabine, capecitabine and mitotane combination 
regimen, showing a clinical complete response of liver metastases and local recurrence at CT scan. 
She is presently disease-free after 22 months from the start of the second line treatment (case #13).  
Among the five patients with early stage ACC who had radical surgery, one developed lung 
metastases (case #5) and one (case # 12) had a local recurrence after 6 months and 16 years, 
respectively. Patient #12 underwent a radical removal of her recurrence and commenced adjuvant 
mitotane treatment. At the last follow-up examination (January 2010), six patients are alive, while 6 
patients died of disease; the median overall survival was 30 months (range 5-204). 
Pathological features (Table 1) – The gross features of myxoid ACT were not significantly different 
from those of conventional ACC, except that in the pure forms there were translucent grey or white 
areas visible on gross inspection (Figure 1). Histologically, all 14 tumors exhibited a more or less 
abundant myxoid component, ranging from focal areas (approximately 5% of the tumor) to virtually 
the entire neoplasm. Within the myxoid background, two different cellular growth patterns were 
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recognized (Figure 2). The first was peculiar and was seen in ten cases, mostly associated with 
prominent myxoid changes. It was characterized by an homogeneous growth of small regular cells 
arranged in cords and microcysts, in some areas very reminiscent of adenoid cystic carcinoma. The 
second pattern, present in the remaining cases (all of which had a focal myxoid background) was 
characterized by a cellular growth similar and indeed merging with that of the conventional ACC 
component in terms of cell size (large), cell appearance (atypia, eosinophilic cytoplasm) and cell 
arrangement (lack of trabeculae and microcysts).  
In summary, trabecular structure, cell type and tumor size (small versus large) distinguished two 
groups, as follows: 
Myxoid ACC - Group 1 (cases #1 to #10) – Case #1 and #2 had small pseudoglandular structures or 
slightly larger microcysts containing an amorphous myxoid material. A trabecular architecture was 
focally recognized in both cases (10-15% of the tumor).  Myxoid lakes were prominent in case #1, 
only. The tumor cells were mostly uniform and homogeneous, with scant lightly eosinophilic 
cytoplasm and lack of nuclear atypia, more reminiscent of zona glomerulosa cells than the large 
foamy cells of the other fasciculate layer. The mitotic index was very low. No necrosis was present 
in either case. All of the unfavorable morphological parameters of the Weiss scoring system were 
absent, except for the fact that clear cell cytoplasm was present in less than 25% of the tumor cells. 
Of the ACC present in this group (cases #3 to #10), a pure or predominant (>70%) myxoid pattern 
was seen in 4 cases (cases #3 to #6), while in the other four tumors (cases #7 to #10), only a limited 
amount (5-25%) of myxoid background was detected. In all cases, the myxoid background was 
associated to a trabecular, pseudoglandular or cribriform growth of small lightly eosinophilic cells. 
The extent of the myxoid background was highly variable, with extracellular material being 
abundant in some areas, where the cells were arranged in thin cords or isolated in the myxoid 
material. In some cases (such as case #3), a more solid growth was found, with an organoid 
(carcinoid-like) pattern and scant myxoid material surrounding the tumor nests. In another case 
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(case #8), a peculiar arrangement of cells in festoon-like structures surrounded by myxoid material 
was observed. Cell atypia was remarkably scant and cell size was small to medium, with the 
exception of one case (case #4) that, despite a similar architecture and prominent myxoid 
background, was huge (over 30 cm, 3200 g), aggressive (Weiss score 7), and characterized by 
atypical and deeply eosinophilic cells arranged in cords or small clusters or even isolated in a 
myxoid background. These features were also detected in the areas of tumor invasion of the 
periadrenal adipose tissue. The extent of pleomorphism raised the alternative possibility of a 
sarcomatous tumor, such as myxoid chondrosarcoma, but the immunophenotype proved the 
adrenocortical origin of the tumor.   
Conventional ACC with focal myxoid degenerative changes - Group 2 (#11 to #14) - This group of 
tumors was characterized by a myxoid component which never exceeded 20% of the lesion. It 
contained much larger cells with the eosinophilic cytoplasm and the nuclear atypias that one sees in 
conventional ACC, with which this myxoid component was actually intermingling. All of these 
cases were in the malignant category, with a Weiss score ranging from 4 to 9. As outlined in Table 
2, except for the presence of focal stromal myxoid changes, tumors in Group 2 are very similar to 
conventional ACCs and more likely represent the result of degenerative myxoid changes rather than 
belong to the distinctive myxoid variant of ACTs described in Group 1 tumors.  
Histochemical and immunohistochemical features - The myxoid areas were positive with the Alcian 
blue staining. In all malignant cases and in  the morphologically borderline case (# 1), reticulin stain 
confirmed the stromal framework disruption, as recently reported by our group (27), while case #2 
had an intact reticulin network. All tumors in this series shared the expression of the known markers 
of the adrenal cortex, namely melan A, α-inhibin, vimentin, and synaptophysin. Cytokeratin was 
expressed in 5/14 cases, always focally, except for case #2, in which there was a diffuse and strong 
immunoreactivity. The mean Ki-67 proliferation index was 31.8% in malignant cases  (# 3-14) and 
only 3 and 4% in the borderline cases # 1 and 2, respectively. A peculiar expression of 
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neurofilaments (as diffuse cytoplasmic, or small paranuclear dots) was observed in 50% of the 
cases, and was associated more to the extent of myxoid changes (all but one positive cases with 
predominant myxoid features) (Figure 3), rather than to the cellular subgroups (Group 1 vs Group 2 
tumors). Such reactivity was observed using an antibody to total neurofilament proteins, and it was 
confirmed using antibodies selective for the different neurofilament subunits. In particular, while no 
signal was found for the 200 kDa neurofilament subunit and only rare tumor cells reacted for the 
160 kDa subunit, all cases expressed the 68 kDa subunit protein, with a pattern similar to that above 
described. As revealed with the double immunostaining procedure, neurofilaments were co-
expressed with the adrenocortical marker melan A in the tumor cells (Figure 3). In the control 
cases, 17 of 47 conventional ACCs (40.4%) were found to express neurofilaments, with a focal 
paranuclear dot-like reactivity in 12 (25.2%) tumors and a granular cytoplasmic positivity in up to 
25% of tumor cells of the remaining seven neoplasms. By contrast, no neurofilament reactivity was 
seen in ACA. As described above, CD99 was positive in the recurrent lesion of case #1 but not in 
the corresponding primary lesion nor in any other case of the series tested, including the control 
ACC TMA cases.  
The unexpected expression of a neural and neuroendocrine marker in a mesodermally derived 
tumor, paralleled by the known expression of synaptophysin by ACC, prompted the investigation of 
further neural or neuroendocrine markers. Of these, only CD56 was intensely expressed in all cases 
(although it was also focally or diffusely expressed in up to 90% of conventional ACC; Volante & 
Papotti 2009, unpublished observation), whereas no reactivity was found for synapsin (except for a 
single case with focal reactivity), CD57, chromogranin A, or hASH1, the latter being a transcription 
factor of the Notch pathway that regulates neuroendocrine differentiation during development.  
Comparison with the immunophenotype of the normal adrenal gland –  The adult and fetal adrenal 
glands showed the expected immunoprofile, with melan A and α-inhibin expression in the cortex 
and neuroendocrine marker reactivity in the medulla. No neuroendocrine marker (chromogranin A, 
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NSE, CD57, CD56 and hASH1) reactivity was seen in the adult or fetal adrenal cortex, with the 
exception of synaptophysin (present in both fetal and adult cortex) and of neurofilaments. The latter 
were expressed only in extremely rare cells of the zona glomerulosa of a single adult adrenal gland 
(case #2), all other adult adrenal gland tissue being negative. However, a strong neurofilament 
reactivity was found in small cells arranged singly or in small clusters in the peripheral layers of all 
8 fetal adrenal cortices investigated (Figure 3). There was a slight decrease of the number of 
reactive cell with increase of the gestational age. The type of neurofilaments expressed in individual 
adrenal cortical cells was mostly the 68 kDa subunit. There were very rare cells which also stained 
for the 160 (but not the 200) kDa subunit, paralleling the reactivity above described in the myxoid 
tumors. 
 
DISCUSSION  
In this study, we describe the clinico-pathological and immunophenotypic features of 14 ACT 
having varying degrees of distinctive myxoid features. Most of these cases had malignant features, 
with a Weiss score of 1 found in two cases only, one of the cases eventually displaying an 
aggressive clinical course with fatal outcome.  
In a review of a large series of ACC at our Institution, myxoid features were observed in 
approximately 10% of the cases and accounted for 5 to 90% of the tumor cell population in 
individual cases, being in general associated and often intermingled with areas of conventional 
ACC. This wide variability in the extent of the myxoid component was associated to distinctive 
growth patterns, which have been only partially addressed in previous reports. In the literature, the 
extension of myxoid changes in single tumors has only been reported by Brown and coworkers (4), 
who indicated a variable percentage of myxoid areas (from 10 to 95%) in their 14 tumors, these 
changes being generally higher in the benign cases. In another single case report (17), large pools of 
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myxoid material were described which involved most of the tumor.  
Morphological features – Although the appearance of the myxoid background was not 
different from that of a variety of human tumors with myxoid features, i.e. mostly characterized by 
more or less extensive areas of extracellular accumulation of light basophilic amorphous material, 
the cell population present within the myxoid material had distinctive characteristics in our series. 
In some cases (Group 2 - # 11 to 14), the tumor cells were very similar to those of conventional 
ACC, i.e. large, irregularly shaped and deeply eosinophilic. The nuclei were large, atypical, and 
with prominent nucleoli. These cells were arranged in irregular nests or cords and merged with 
areas of conventional ACC having a diffuse growth pattern. In our view, these cases represent 
classical ACC having more or less extensive (5 to 20% of the tumor area) accumulation of myxoid 
material, probably as a result of focal intratumoral degenerative changes. The other cases (Group 1 - 
#1 to #10) had a different architecture and apparently form a separate group of ACT having 
distinctive histological features, already recognized by some workers (4). These tumors had a 
relatively homogeneous growth pattern made of small-to-medium sized cells with minimal atypia, 
arranged in thin trabeculae, pseudoglands or small cysts, resembling the patterns of adenoid-cystic 
carcinoma in a more or less abundant myxoid stroma. With regard to the malignant cases, the well 
known features of classical ACC, as summarized in the nine Weiss score parameters, were not 
readily apparent, with the exception of “dark” cell cytoplasm, mitotic figures, and necrosis. The 
other Weiss score parameters could be identified in a variable percentage, but some of these criteria 
were hard to assess in the myxoid areas. Among them, small vessel invasion was less apparent due 
to the myxoid background, and diffuse growth pattern was never a feature in these tumors, whereas 
atypia was minimal or absent. For these reasons, and as already reported for other ACC variants, 
such as the oncocytic ACC (2) or the pediatric ACCs (5), Weiss criteria might be inadequate to 
reliably detect malignancy in myxoid ACC. Moreover, when these distinctive morphological 
features are predominant in an adrenal tumor, the differential diagnosis should include several types 
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of metastatic tumors, including breast carcinoma, salivary or skin adnexal carcinomas of the 
adenoid cystic type, and neuroendocrine tumors. All of these tumors are potentially capable of 
giving metastatic spread to the adrenal gland, and an immunohistochemical marker profile is 
therefore mandatory.  
Immunophenotype - The immunohistochemical profile of both the conventional ACC with a 
myxoid component (Group 2) and the pure myxoid ACT (Group 1) is similar to that of classical 
ACC. Thus, melan A and α-inhibin are regularly present in myxoid tumors, as is synaptophysin 
(12,18). A correct definition of the adrenocortical origin can therefore be obtained in all cases, 
irrespective of their myxoid material content. Focal or diffuse cytokeratin expression was observed 
in approximately 60% of cases, while in all (except case # 2) tumors, the reticulin stain 
demonstrates architectural disruption, which was recently described as a major marker of ACC (27). 
The Ki-67 proliferation index in myxoid ACC was not different from that of conventional ACC, 
being on average 31.8% in malignant cases as opposed to 3 and 4% in the borderline cases, 
respectively.  
A distinctive feature was the expression of neurofilament proteins in the small cell, 
pseudoglandular or trabecular areas of cases having a predominant (i.e. > 70% of tumor) myxoid 
component (#1 to #6), in a fraction of tumor cells generally not exceeding 15-25% of the tumor 
population (with the exception of case # 2). Neurofilaments were generally absent in cases with 
only focal myxoid stromal component, with the exception of cases #10, 11 and 13, which showed 
focal neurofilaments reactivity in single cells. Neurofilament expression in ACC has been reported 
previously in the Literature only once and in a limited series of cases, apparently without any 
association with specific morphological features (20). As a matter of fact, neurofilament expression 
is instead considered a marker of adrenal medullary cells and their tumors. To test whether 
neurofilament expression was restricted to the myxoid and small cell ACC here described, a series 
of conventional ACC was tested and neurofilaments were found to be expressed in 19/47 cases 
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(40.4%). The extent of the reactivity was mostly focal (12 cases) and restricted to a small 
paranuclear dot, but seven cases had a more diffuse, finely granular cytoplasmic positivity in up to 
25% of the tumor cells. These findings indicate that neurofilament expression is characteristic of 
predominantly myxoid ACCs, but that it also occurs in a fraction of conventional ACC, thus 
expanding the list of neural and neuroendocrine markers detected in adrenocortical cells and 
tumors, such as synaptophysin (12,18). Whether ACC in general and its myxoid variants in 
particular are tumors having a divergent differentiation towards endocrine (steroid-producing) and 
neuroendocrine lineages is not known. Along these lines, other neuroendocrine markers were tested 
in the current cases (as well as in the fetal normal glands), including chromogranin A, synapsin, 
CD57 and CD56. Only the latter was found positive in all tested cases, but it is known that CD56 is 
highly expressed in normal adrenal cortex and derived tumors (22,24). It is worth noting, however, 
that in focally myxoid tumors the expression of neurofilaments and CD56 was mostly restricted to 
the myxoid areas. To further explore the neural/neuroendocrine phenotype of these rare myxoid 
tumors, the expression of transcription factors driving neuronal and endocrine differentiation during 
the embryonal life and in some neuroendocrine tumors was also assessed, with special reference to 
hASH1 (human achete scute homologue 1), but no immunoreactivity was found for this marker in 
any tumor.  
Interestingly, although the peritumoral adrenal cortex of the current cases was totally 
unreactive to neurofilaments (with the exception on scattered cells in case #2), a consistent  
immunoreactivity was observed in subcapsular cortical isolated cells or clusters of the fetal adrenal 
gland when antibodies specific to the 68 and 160 kDa neurofilament subunits were employed. A 
similar observation had already been mentioned in an old study on fetal and adult human adrenal 
medullary cells, in which the authors quoted as a “peculiar phenomenon” the expression of medium 
molecular weight neurofilament subunits through all adrenocortical developmental stages and also 
in the adult adrenal cortex (21). 
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Clinical features – Most myxoid ACT (71%) in our series were functioning malignant 
neoplasms, with  greater frequency of Cushing-related symptoms.  The rate of functioning tumors 
of the present series is in line with the literature data on the 13 currently reported malignant ACC 
with myxoid features (3-5,12,18,28) and is higher than that generally recorded in conventional 
ACC, ranging from less than 50% in our experience (27) to 60% in the literature (8). Unfortunately, 
from the literature review, it seems that some heterogeneity exists in the reported cases, in that some 
of these cases probably represent examples of conventional ACC having focal myxoid changes and 
containing large eosinophilic atypical cells. The true clinical behavior of pure myxoid ACA and 
ACCs is difficult to assess. Brown et al (4) reported 14 cases, comprising 6 benign and 8 malignant 
tumors. The latter (which had myxoid areas in 10 to 60% of the tumor mass) followed an aggressive 
course in 50% of cases. However, the benign tumors had frequently a large size (>5 cm in four 
cases), questionable capsular invasion (in four cases) and a mitotic activity potentially exceeding 
the cutoff of 5/50HPF (four cases had one or more mitoses in 10 HPF). In the present series, a case 
originally considered of borderline malignancy (Weiss score 1) developed peritoneal spread and 
eventually killed the patient five years after diagnosis. The 12 ACC cases had a Weiss score of 3 to 
9 and metastatic disease at diagnosis in five instances. With regard to the outcome data, in the 
absence of a comparable control group, it is difficult to state whether patients with ACT with 
myxoid features have a survival different from unselected ACC patients, and the responsiveness of 
myxoid ACT to systemic chemotherapy (8) warrants further testing.  
In conclusion, myxoid changes rarely occur in ACT. They are identified most frequently in 
malignant or borderline tumors, and are associated to two distinctive cellular growth patterns, one 
similar to conventional ACC, and the other representing a morphologically distinct entity made up 
of small-to-medium sized cells with minimal atypia, arranged in trabecular, pseudoglandular or 
small cystic spaces in a myxoid background which may represent up to 90% of the tumor cell 
population. Their immunoprofile overlaps with that of conventional ACTs. Interestingly, 
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neurofilament expression, only focally and inconsistently present in conventional ACC, emerged as 
a distinctive feature of predominantly myxoid tumors, and was paralleled by a similar neurofilament 
reactivity in the normal fetal adrenal cortex, too. 
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FIGURE LEGENDS 
 
Figure 1 - Gross features of case # 1 (a) showing a well circumscribed yellowish  mass having 
extensive translucent appearance, corresponding to the myxoid areas observed in the low power 
view of the tumor (b) in which microcystic spaces contain basophilic material. A huge 
adrenocortical carcinoma (case #10) (c) has extensive necrotic areas and a solid withish portion 
(top) with translucent appearance, which corresponds to the myxoid lakes found at the microscopic 
level (d). [Hematoxylin & Eosin, original magnification 100x in b, 200x in d]. 
 
 
Figure 2 – Pure myxoid tumors are made of cords or small glands or cysts of small uniform cells 
(a-b) with more or less extensive myxoid background. In some cases, tumor nests and cords contain 
myxoid material and small-medium size cells with minimal atypias (c). This architecture can also 
be detected in small biopsy samples, as in the case # 6, predominantly characterized by small 
eosinophilic cells in a myxoid matrix (d). Conventional adrenocortical carcinomas having focal 
myxoid changes may show areas of transition  from classical solid and diffue growth (e, bottom-
left) to myxoid pattern (e, top-right). The extent of myxoid material accumulation is variable and 
cells are generally isolated or in small cords (f). Cytologically, remarkable atypias are generally 
present  in large eosinophilic cells growing in the myxoid background (g). [Hematoxylin & Eosin, 
original magnification 100x in a, 200x in b-c-e, 400x in d-f; 600x in g]. 
 
Figure 3 – Immunoreactivity for Melan A in a peripheral area of case # 2 including adrenal cortex 
(a, left) and small strongly reactive tumor cells in pseudoglands and microcysts (a, right). The same 
tumor area is also intensely expressing neurofilament proteins in most cells (b). In the same case, a 
double immunohistochemical stain for Melan A (brown color) and neurofilaments (blue color) 
revealed a co-expression ofthese markers in the same cells (a-b, inset). An adrenocortical carcinoma 
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with focal myxoid changes has neurofilament reactivity mostly restricted to the myxoid component 
(c, bottom-right; same case as Fig 1d). In fetal adrenal gland at 12 week gestation, the cortex is 
diffusely positive for Melan A (d), while some subcapsular cells of an adjacent section are 
neurofilament reactive in thin cytoplasmic protrusions or in a paranuclear dot or cap (e). 
[Immunoperoxidase, original magnification 100x in a-c, 200x in d-e. Inset: double 
immunoperoxidase and alcaline phosphatase, 600x]. 
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Table 1. Clinical and pathological features of myxoid adrenocortical neoplasms. 
# Sex/ 
age 
Hormonal 
status 
Site Stage Surgery Weight 
(g) 
Size 
(cm) 
Diagnosis Myxoid 
area (%) 
Growth pattern 
(predominant) 
Weiss 
score 
Ki-67 
(%) 
NF IHC Mitotane/ 
 other 
Rec/mets Status 
(months) 
GROUP 1 – MYXOID ADRENOCORTICAL TUMORS         
1 M/58 NF R 1 radical 55 5 T-UMP 90 trabecular, 
microacinar 
1 4 + foc mit^ local & 
peritoneal 
(60mos) 
DOD 68 
2 F/52 NF L 1 radical 20 4 T-UMP 90 trabecular, 
microacinar 
1 3 + - - NED 9 
3 F/72 cort/andr L 4 non rad 200 9 ACC 70 trabecular 5 70 - mit lung (at dx) DOD 18 
4 M/43 cortisol L 1 radical 3200 30 ACC 90 trabecular, solid 7 15 + mit - NED 9 
5 M/47 NF L 2 radical 1000 25 ACC 85 trabecular, solid 7 na + EDP+mit local, liver, 
lung (6mos) 
DOD 33 
6 F/70 cort/andr R 4 no (biopsy) na ACC 75 trabecular na na na mit liver, lung, 
bone (at dx) 
DOD 5 
7 M/66 cortisol L 4 non rad 250 9 ACC 15 conv & focal 
trabecular 
8 35 - mit lung (at dx) DOD 8 
8 F/60 cortisol L 4 radical 60 5 ACC 20 conv & focal 
trabecular 
4 20 - EDP+mit local & lung 
(14mos) 
DOD 29 
9 F/43 cortisol L 4 non rad 700 10 ACC 5 conv & focal 
trabecular 
8 50 - EDP+mit lung (at dx) AWD 8 
10 F/53 NF L 4 radical§ 3000 28 ACC 20 conv & focal 
trabecular 
9 30 + foc EDP+mit lung (at dx) NED 9 
GROUP 2 – CONVENTIONAL ACC WITH FOCAL MYXOID DEGENERATIVECHANGES       
11 M/43 cortisol R 1 radical 60 5 ACC 20 solid, atypias 4 5 + foc - - NED 9 
12 F/52 cortisol L 2 radical# 300 10 ACC 20 solid, atypias 5 40 - mit local (192mos) NED 204 
13 F/53 cortisol R 2 radical 250 10 ACC 10* solid, atypias 6 35 + foc EDP+mit local & liver 
(3mos) 
NED 36 
14 F/68 androgens L 3 radical 260 10 ACC 5 solid, atypias 9 25 - EDP+mit local (6mos), 
liver, lung 
(7mos) 
DOD 15 
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Abbreviations: M: male; F: female; NF: non functioning; cort: cortisol; andr: androgens; R: right; L: left; non rad: non radical surgery; §: surgery 
performed after chemotherapy; #: after local recurrence, the patient underwent a second radical surgery and adjuvant mitotane; na: not available; T-
UMP: tumor of uncertain malignant potential; ACC: adrenocortical carcinoma; *: both primary and local recurrence; conv: conventional ACC 
growth patterns; NF: neurofilaments; IHC: immunohistochemistry; foc: focal; mit: mitotane; ^: administrated at the time of tumor recurrence and 
progression; EDP: etoposide, doxorubicin, cisplatin 
mos: months; at dx: at diagnosis; NED: no evidence of disease, AWD: alive with disease; DOD: died of disease.  
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Table 2. Distinctive features of myxoid ACC and conventional ACC with focal myxoid changes 
Myxoid ACC  
(Group 1, cases #1-10) 
Pathological feature Conventional ACC with focal 
myxoid degenerative changes  
(Group 2, cases #11-14) 
Separated from conventional 
areas if any, extensive in 6/10 
cases 
 
Type of myxoid changes Merged with conventional ACC 
areas, and always focal (<20% 
of the tumor area) 
 
Usually trabecular, microacinar Growth pattern As conventional ACC, usually 
solid/diffuse 
Small, uniform Cell size Large, heterogeneous 
Mild* Nuclear atypia Moderate to high 
Scant, eosinophilic Cell cytoplasm Abundant, granular 
eosinophilic 
 Present in 5/9 cases, generally 
diffuse  
Neurofilament expression Present in 2/4 cases, focal 
 
 
Notes. ACC: adrenocortical carcinoma; *: high in case #4.  
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